Study Finds that Use of an Impedance Threshold Device Combined with High Quality CPR and Adherence to AHA Guidelines Increases Neurologically-Intact Survival Rate from In-hospital Cardiac Arrest to 30 Percent
Minneapolis, MN - A recent study presented by Ken Thigpen, RRT (St. Dominic-Jackson Memorial Hospital; Jackson, Mississippi) at the 2013 American Heart Association (AHA) Scientific Sessions found that use of the ResQPOD® Impedance Threshold Device (ITD), combined with high quality CPR in accordance with AHA Guidelines, helped to increase neurologically-intact survival following in-hospital cardiac arrest from 17.2% in 2005 to 30.1% in 2012 – a 75% improvement (p<0.01). The study assessed the survival impact of the 2005 and 2010 AHA Guidelines, which include ITDs and emphasize the performance of high quality CPR in a medium-size hospital. In addition, 75% of the survivors between 2010 and 2012 had a favorable neurologic recovery (cerebral performance category score of <3). This 30% survival rate is twice the national average for survival following inhospital cardiac arrest, which is approximately 15% in US hospitals within the Get With The Guidelines Resuscitation Registry.
The study’s authors conclude “These findings demonstrate the enormous clinical benefits associated with focusing on provider engagement in effective delivery of CPR, including delivery of consistent chest compressions, full chest wall recoil, minimal interruptions, ITD use, and the overall ‘pit crew’ approach.”
These data further validate that the intrathoracic pressure regulation (IPR) provided by the ResQPOD ITD improves circulation. IPR is a novel therapy that regulates pressure in the chest to reduce intracranial pressure and maximize the blood drawn into and pushed out of the heart with each heartbeat (if the patient has a pulse), or with each chest compression if the patient is receiving cardiopulmonary resuscitation (CPR). The ResQPOD ITD is used by health care professionals both inside and outside the hospital during the administration of CPR. Studies have shown that during CPR, the ResQPOD doubles blood flow to the heart, increases blood flow to the brain by 50%, doubles systolic blood pressure, and increases survival rates with favorable neurologic outcomes by 25% or more. Timing lights promotes the performance of high quality CPR. The ResQPOD is FDA 510(k) cleared, CE marked and is patent protected globally.
Advanced Circulatory is the developer of the ResQPOD and ResQGARD ITDs and has pioneered the IPR therapy platform, which has far-reaching implications for multiple medical conditions. It increases circulation, protecting the heart, brain and other vital organs when blood flow is compromised, giving rescuers, clinicians and caregivers the potential to return patients to a full life after critical medical emergencies. The company’s products are sold in over 25 countries worldwide.